JP2024523623A5 - - Google Patents

Info

Publication number
JP2024523623A5
JP2024523623A5 JP2023580488A JP2023580488A JP2024523623A5 JP 2024523623 A5 JP2024523623 A5 JP 2024523623A5 JP 2023580488 A JP2023580488 A JP 2023580488A JP 2023580488 A JP2023580488 A JP 2023580488A JP 2024523623 A5 JP2024523623 A5 JP 2024523623A5
Authority
JP
Japan
Prior art keywords
diol
amino
propane
phthalazine
hydroxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023580488A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024523623A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2022/068292 external-priority patent/WO2023275366A1/en
Publication of JP2024523623A publication Critical patent/JP2024523623A/ja
Publication of JP2024523623A5 publication Critical patent/JP2024523623A5/ja
Pending legal-status Critical Current

Links

JP2023580488A 2021-07-02 2022-07-01 Nlrp3インフラマソーム阻害剤 Pending JP2024523623A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163217970P 2021-07-02 2021-07-02
US63/217,970 2021-07-02
PCT/EP2022/068292 WO2023275366A1 (en) 2021-07-02 2022-07-01 Nlrp3 inflammasome inhibitors

Publications (2)

Publication Number Publication Date
JP2024523623A JP2024523623A (ja) 2024-06-28
JP2024523623A5 true JP2024523623A5 (cg-RX-API-DMAC7.html) 2025-06-30

Family

ID=82611090

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023580488A Pending JP2024523623A (ja) 2021-07-02 2022-07-01 Nlrp3インフラマソーム阻害剤

Country Status (31)

Country Link
US (2) US11970463B2 (cg-RX-API-DMAC7.html)
EP (2) EP4628490A3 (cg-RX-API-DMAC7.html)
JP (1) JP2024523623A (cg-RX-API-DMAC7.html)
KR (1) KR20240031343A (cg-RX-API-DMAC7.html)
CN (1) CN117580826A (cg-RX-API-DMAC7.html)
AR (1) AR126351A1 (cg-RX-API-DMAC7.html)
AU (2) AU2022304254B2 (cg-RX-API-DMAC7.html)
BR (1) BR112023026976A2 (cg-RX-API-DMAC7.html)
CA (1) CA3224513A1 (cg-RX-API-DMAC7.html)
CL (1) CL2023003939A1 (cg-RX-API-DMAC7.html)
CO (1) CO2024000565A2 (cg-RX-API-DMAC7.html)
CR (1) CR20240038A (cg-RX-API-DMAC7.html)
DK (1) DK4363406T3 (cg-RX-API-DMAC7.html)
DO (1) DOP2024000002A (cg-RX-API-DMAC7.html)
EC (1) ECSP24008862A (cg-RX-API-DMAC7.html)
ES (1) ES3054790T3 (cg-RX-API-DMAC7.html)
FI (1) FI4363406T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20251513T1 (cg-RX-API-DMAC7.html)
IL (1) IL309680A (cg-RX-API-DMAC7.html)
LT (1) LT4363406T (cg-RX-API-DMAC7.html)
MA (1) MA65277B1 (cg-RX-API-DMAC7.html)
MX (1) MX2024000234A (cg-RX-API-DMAC7.html)
PE (1) PE20250122A1 (cg-RX-API-DMAC7.html)
PL (1) PL4363406T3 (cg-RX-API-DMAC7.html)
PT (1) PT4363406T (cg-RX-API-DMAC7.html)
RS (1) RS67463B1 (cg-RX-API-DMAC7.html)
SI (1) SI4363406T1 (cg-RX-API-DMAC7.html)
SM (1) SMT202500441T1 (cg-RX-API-DMAC7.html)
TW (1) TW202321201A (cg-RX-API-DMAC7.html)
UY (1) UY39839A (cg-RX-API-DMAC7.html)
WO (1) WO2023275366A1 (cg-RX-API-DMAC7.html)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11618751B1 (en) 2022-03-25 2023-04-04 Ventus Therapeutics U.S., Inc. Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 derivatives
TW202231281A (zh) * 2020-12-25 2022-08-16 大陸商上海拓界生物醫藥科技有限公司 一類含噠嗪的化合物及其醫藥用途
US11319319B1 (en) 2021-04-07 2022-05-03 Ventus Therapeutics U.S., Inc. Compounds for inhibiting NLRP3 and uses thereof
EP4347571B1 (en) 2021-06-04 2026-04-22 F. Hoffmann-La Roche AG Triazine derivatives and their use in the treatment of cancer.
CA3226995A1 (en) * 2021-07-21 2023-01-26 Nico Therapeutics, Inc. Annulated pyridazine compound
IL310992A (en) * 2021-08-25 2024-04-01 Ptc Therapeutics Inc NLRP3 inhibitors
WO2023051761A1 (zh) * 2021-09-30 2023-04-06 成都奥睿药业有限公司 一类取代杂芳酞嗪衍生物的药学用途及其制备方法
WO2023066377A1 (zh) 2021-10-22 2023-04-27 索智生物科技(浙江)有限公司 一种含氮化合物、其制备方法及应用
US12331048B2 (en) 2022-10-31 2025-06-17 Ventus Therapeutics U.S., Inc. Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 inhibitors
KR20250162767A (ko) * 2022-12-28 2025-11-19 아스트라제네카 아베 Nlrp3 인플라마좀 억제제의 결정질 형태, 화학 공정 및 화학적 화합물
CN120418236A (zh) 2022-12-28 2025-08-01 长春金赛药业有限责任公司 哒嗪类nlrp3抑制剂化合物、药物组合物及其制备方法和应用
AU2024280075A1 (en) 2023-06-02 2025-12-11 Merck Sharp & Dohme Llc 5,6-Unsaturated Bicyclic Heterocycles Useful as Inhibitors of Nod-Like Receptor Protein 3
KR20250074627A (ko) * 2023-11-20 2025-05-27 벤투스 테라퓨틱스 유에스 인코포레이티드 NLRP3을 억제하기 위한 5-클로로-2-(4-((2-하이드록시-2-메틸프로필)아미노)피리도[3,4-d]피리다진-1-일)페놀의 고형 유리염기 형태 및 이의 용도
TW202545527A (zh) 2024-01-16 2025-12-01 英商諾得瑟拉公司 Nlrp3及glp-1a組合療法
WO2026006510A1 (en) * 2024-06-26 2026-01-02 Virginia Commonwealth University Compounds as nlrp3 inhibitors, and compositions and uses thereof
WO2026002229A1 (zh) * 2024-06-28 2026-01-02 长春金赛药业有限责任公司 一种nlrp3抑制剂化合物及其制备方法和应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1745039A4 (en) 2004-05-08 2009-07-22 Neurogen Corp 3-ARYL-5,6-DISUBSTITUTED PYRIDAZINES
CN111315733A (zh) * 2017-11-09 2020-06-19 英夫拉索姆有限公司 新颖磺酰胺甲酰胺化合物
AR119731A1 (es) 2019-05-17 2022-01-05 Novartis Ag Inhibidores del inflamasoma nlrp3
CN115279739B (zh) 2020-03-27 2025-07-22 尼科治疗有限公司 取代哒嗪化合物
TW202231281A (zh) 2020-12-25 2022-08-16 大陸商上海拓界生物醫藥科技有限公司 一類含噠嗪的化合物及其醫藥用途
EP4289823A4 (en) 2021-02-08 2025-02-26 Medshine Discovery Inc. SUBSTITUTED PYRIDAZINE PHENOL DERIVATIVES
US11319319B1 (en) * 2021-04-07 2022-05-03 Ventus Therapeutics U.S., Inc. Compounds for inhibiting NLRP3 and uses thereof
WO2022230912A1 (ja) 2021-04-28 2022-11-03 アステラス製薬株式会社 置換トリアジン化合物
JP2024529839A (ja) 2021-06-29 2024-08-14 ズーマゲン バイオサイエンシーズ エルティーディー Nlrp3モジュレーター

Similar Documents

Publication Publication Date Title
FI4363406T3 (fi) Nlrp3-inflammasomin estäjiä
JP2021502323A5 (cg-RX-API-DMAC7.html)
CA2695757C (en) Phenylacetic acid compound
JP2011513367A5 (cg-RX-API-DMAC7.html)
JP2014037426A5 (cg-RX-API-DMAC7.html)
JP2013543896A5 (cg-RX-API-DMAC7.html)
JP2004524308A5 (cg-RX-API-DMAC7.html)
JP2007502804A5 (cg-RX-API-DMAC7.html)
JP2009539828A5 (cg-RX-API-DMAC7.html)
JP2009532417A5 (cg-RX-API-DMAC7.html)
IL287159B2 (en) Small molecules agonists for FXR (farnesoid X receptor) and method for their preparation and use
CA2541781A1 (en) 3-hydroxymethyl-4-hydroxy-phenyl derivatives for the treatment of respiratory illnesses
JP2017522348A5 (cg-RX-API-DMAC7.html)
RU2010149611A (ru) Ациламинозамещенные производные конденсированных циклопентанкарбоновых кислот и их применение в качестве фармацевтических средств
RU2007106037A (ru) Производные пиримидисульфонамида в качестве модуляторов рецепторов хемокинов
RU2005106356A (ru) Новое соединение
JP2005500370A5 (cg-RX-API-DMAC7.html)
RU2005106355A (ru) Новое соединение
JP2011506294A5 (cg-RX-API-DMAC7.html)
JP2007518798A5 (cg-RX-API-DMAC7.html)
JP2010517983A5 (cg-RX-API-DMAC7.html)
CN110612286A (zh) 氰基取代的稠合双环衍生物及其制备方法和用途
JP2024539922A5 (cg-RX-API-DMAC7.html)
JP2008524186A5 (cg-RX-API-DMAC7.html)
KR101763740B1 (ko) 탄소환 뉴클레오시드 및 이들의 약학적 용도 및 조성물